Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
← catalyst calendarNCT06192758 · readout ≤ 529 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
36estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-15 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Prostate
- Cancer
Intervention
- Device: TheraSphere PCa — also filed as TheraSphere PCa - Yttrium-90 Glass Microspheres
Primary outcome
what the primary-completion date above is the date OFMaximum tolerated radiation dose of TheraSphere PCa
measured Through 90 days post-treatment
Publications
- PMID 33839262 — cited as background
- PMID 29769209 — cited as background
- PMID 41276366 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed